Updated results from the phase 3 CheckMate-8HW trial continue to show fewer severe (grade 3/4) side effects with nivolumab/ipilimumab compared to chemotherapy.
Adults aged 70 or over account for more than a third of all new cancer diagnoses globally [1]. Despite continuous efforts in the last decades,…
The FDA released a draft guidance document detailing their interpretation of when a confirmatory clinical trial for an accelerated approval is underway.
The prevalence of metabolic syndrome in the recruited nationwide childhood cancer survivor cohort was high and inconsistent with the chronological age, suggesting a substantial future…
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
An abstract is unavailable.
Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.
Edited by Associate Editor Hervé Dombret, this How I Treat series highlights the clinical approach to high-risk subgroups of acute lymphoblastic leukemia (
Key PointsFor PCNSL, PFS was favorable with RD-WBRT consolidation.RD-WBRT can be more frequently considered for consolidation in lieu of nonmyeloablative c
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive…
A study observed differences between expected and observed cancer incidence in 2020 and 2021 to evaluate the pandemic’s disruption of cancer detection.
